145742-28-5

Basic information

• Product Name: (2S,3S)-1-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-piperidin-3-amine
• Synonyms: (2S,3S)-1-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-piperidin-3-amine;( )-(2S,3S)-3-(2-Methoxy-5-trifluoromethoxybenzyl)amino-2- phenylpiperidine;3-Piperidinamine, N-((2-methoxy-5-(trifluoromethoxy)phenyl)methyl)-2-phenyl-, (2S,3S)-;3-Piperidinamine, N-((2-methoxy-5-(trifluoromethoxy)phenyl)methyl)-2-phenyl-, (2S-cis)-;Cp 122,721;Cp 122721;Cp-122,721;(+)-CP 122721(CP 122721)
• CAS NO: 145742-28-5
• Molecular Formula: C20H23F3N2O2
• Molecular Weight: 380.4
• Mol File: 145742-28-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 426.3°Cat760mmHg
• Flash Point: 211.6°C
• Appearance: /
• Density: 1.219g/cm³
• CAS DataBase Reference: (2S,3S)-1-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-piperidin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S)-1-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-piperidin-3-amine(145742-28-5)
• EPA Substance Registry System: (2S,3S)-1-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-piperidin-3-amine(145742-28-5)

Safety Data

• Hazardous Substances Data: 145742-28-5(Hazardous Substances Data)

Usage

General Description

The chemical compound "(2S,3S)-1-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-piperidin-3-amine" is a piperidine derivative with a molecular formula C23H29F3N2O. It contains a piperidine ring with an amine group, as well as a phenyl group and a trifluoromethoxy group attached to the piperidine ring. The compound also has a methoxy group attached to the phenyl ring. This chemical structure suggests that it may have pharmaceutical or biological activity, potentially as a receptor modulator or enzyme inhibitor, but further research would be necessary to determine its specific properties and potential applications.

InChI:InChI=1/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-11-5-8-17(24)19(25)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19H,5,8,11,13,24H2,1H3/t17-,19-/m0/s1

Upstream product

• 136871-75-5 (2S,3S)-2-phenyl-3-piperidinamine 
• 145742-65-0 2-methoxy-5-(trifluoromethoxy)benzaldehyde 
• 250589-63-0 (2S,3R)-tert-butyl 3-hydroxy-2-phenylpiperidine-1-carboxylic acid 
• 100-58-3 phenylmagnesium bromide 
• 136982-36-0 (2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine 
• 500021-57-8 (S)-3-[(E)-Methoxyimino]-2-phenyl-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Preparation method of chiral ortho-amino alcohol intermediates, antagonists and analogues of antagonists

The invention belongs to the field of chemical synthesis, relates to a preparation method of chiral ortho-amino alcohols and antagonists, and particularly relates to a preparation method of chiral ortho-amino alcohols and antagonists CP-122, 721 and L-733

Pharmaceutical composition and method of modulating cholinergic function in a mammal

A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed.

Pharmaceutical composition and method of modulating cholinergic function in a mammal

A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed.